MAGE A3/A6 TCR

Drug Profile

MAGE A3/A6 TCR

Alternative Names: anti-MAGE A3/A6 TCR

Latest Information Update: 21 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Cancer Institute (USA)
  • Class Cell therapies
  • Mechanism of Action Gene transference; MAGEA-3-protein-modulators; T lymphocyte replacements; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 21 Mar 2016 Phase-II clinical trials for Solid tumours in USA (Kite Pharma pipeline; March 2016)
  • 29 Feb 2016 Kite Pharma plans to file an IND application with the US FDA for a TCR product candidate that targets a MAGE antigen expressed on Solid tumours (Kite Pharma 8-K; February 2016)
  • 21 Oct 2015 Kite Pharma in-licenses T cell receptor-based products directed against MAGE A3/A6 in Solid tumours expressing MAGE from National Institute of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top